

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation				
<i>Summary of comments, action taken, and justification of action:</i>				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs

Issue date: August 2008

1.	<p>The following group may also be appropriate:</p> <p>Katherine Dormandy Trust</p> <p>The Katherine Dormandy Trust, based in London, UK, believes that a genetic cure for the disease (haemophilia) is very close. It launched an appeal for five million UK pounds to enable researchers to start treating patients with new genetic cures.</p>	Bayer Schering Pharma	Not added	<p><i>This organisation's interests are not closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore Katherine Dormandy Trust has not been added to the matrix.</i></p>
----	---	-----------------------	-----------	---

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs

Issue date: August 2008